TY - JOUR
T1 - Perspectives of HER2-targeting in gastric and esophageal cancer
AU - Gerson, James N.
AU - Skariah, Sam
AU - Denlinger, Crystal S.
AU - Astsaturov, Igor
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/5/4
Y1 - 2017/5/4
N2 - Introduction: The blockade of HER2 signaling has significantly improved the outlook for esophagogastric cancer patients. However, targeting HER2 still remains challenging due to complex biology of this receptor in gastric and esophageal cancers. Areas covered: Here, we review complex HER2 biology, current methods of HER2 testing and tumor heterogeneity of gastroesophageal cancer. Ongoing and completed clinical research data are discussed. Expert opinion: HER2 overexpression is a validated target in gastroesophageal cancer, with therapeutic implications resulting in prolonged survival when inhibited in the front-line setting. With standardized HER2 testing in gastro-esophageal cancer, the ongoing trials are testing newer agents and combinations including combination of anti-HER2 antibodies with immunotherapy. Clonal heterogeneity and emergence of resistance will challenge our approach to treating these patients beyond the frontline settings.
AB - Introduction: The blockade of HER2 signaling has significantly improved the outlook for esophagogastric cancer patients. However, targeting HER2 still remains challenging due to complex biology of this receptor in gastric and esophageal cancers. Areas covered: Here, we review complex HER2 biology, current methods of HER2 testing and tumor heterogeneity of gastroesophageal cancer. Ongoing and completed clinical research data are discussed. Expert opinion: HER2 overexpression is a validated target in gastroesophageal cancer, with therapeutic implications resulting in prolonged survival when inhibited in the front-line setting. With standardized HER2 testing in gastro-esophageal cancer, the ongoing trials are testing newer agents and combinations including combination of anti-HER2 antibodies with immunotherapy. Clonal heterogeneity and emergence of resistance will challenge our approach to treating these patients beyond the frontline settings.
KW - Animals
KW - Antibodies/immunology
KW - Antineoplastic Agents/pharmacology
KW - Esophageal Neoplasms/drug therapy
KW - Humans
KW - Immunotherapy/methods
KW - Molecular Targeted Therapy
KW - Receptor, ErbB-2/metabolism
KW - Signal Transduction/drug effects
KW - Stomach Neoplasms/drug therapy
KW - Survival Rate
UR - http://www.scopus.com/inward/record.url?scp=85018661018&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000400002600002&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1080/13543784.2017.1315406
DO - 10.1080/13543784.2017.1315406
M3 - Review article
C2 - 28387541
SN - 1354-3784
VL - 26
SP - 531
EP - 540
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 5
ER -
